Monday, January 14, 2019
Galmed price target lowered to $28 from $36 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Galmed Pharmaceuticals to $28 after shifting the U.S. launch of Aramchol out to 2022 from 2021 previously. However, with a pivotal path forward for Aramchol, which the analyst notes has been granted Fast Track designation by the FDA for the treatment of nonalcoholic steatohepatitis, he affirms a Buy rating on Galmed shares.
https://thefly.com/landingPageNews.php?id=2848053
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.